COMMUNIQUÉS West-GlobeNewswire

Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
08/09/2025
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel ® for human therapies and [...]
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
08/09/2025
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to follow [...]
CorMedix Announces Strategic Minority Investment in Talphera
08/09/2025
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening [...]
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
08/09/2025
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for [...]
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
08/09/2025
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for [...]
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
08/09/2025
Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the " [...]
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
08/09/2025
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX [...]
Cannabix Technologies to Exhibit at National Safety Council (NSC) Safety Congress and Expo, Denver Colorado
08/09/2025
VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing [...]
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
08/09/2025
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD [...]
Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Program
08/09/2025
Groundbreaking Program Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), [...]
Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Programme
08/09/2025
Groundbreaking Programme Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), [...]
New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions
08/09/2025
Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1 suggesting the impact of continued lifestyle support from Omada SAN [...]
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
08/09/2025
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Journal of Healthcare Management Study Uncovers Critical Gaps in Hospital Employee Surveys Used to Assess Risk of Clinician Turnover, Unveiling Need for Atalan Platform
08/09/2025
Data found 12 times higher risk of turnover among nonresponding clinicians, revealing how nonresponse bias distorts survey results and emphasizing the need for objective data solutions Study co-authored by world- [...]
MediciNova Provides Shareholder Update on Key Developments
08/09/2025
LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
08/09/2025
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today [...]
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
08/09/2025
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN [...]
BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes
08/09/2025
SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BlueGenesLab , a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that [...]
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
08/09/2025
Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset [...]

Pages